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We evaluated short- and long-term effects of high-dose
recombinant human erythropoietin (rHuEPO) in kidney
transplantation in a prospective double-blind, placebo-
controlled study. Patients with chronic kidney disease
following receipt of a deceased donor kidney allograft were
randomized to 3 doses of 40,000 units rHuEPO or placebo.
The primary study end point was kidney function 6 weeks
after transplantation with secondary end points of incidence
of delayed graft function and kidney function 12 months
after transplantation. Six weeks or 12 months after
transplantation, the difference between estimated
glomerular filtration rates was not significant comparing
44 patients who received rHuEPO to 44 patients receiving
placebo. There was no significant difference regarding the
incidence of delayed graft function (10 of 44 with rHuEPO
compared with 14 of 44 on placebo). Protocol biopsies at
6 weeks and 6 months post transplant showed no significant
differences in all assessed histological indices. The number
and severity of adverse events were comparable between
groups, as was patient and graft survival after 12 months.
Thus, treatment with high-dose rHuEPO after kidney
transplantation, although well tolerated, had no effect on
long-term graft function or histology.
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In numerous studies, erythropoietin has revealed pleiotropic
effects well beyond the maintenance of red blood cell mass.1–3
In the embryo, erythropoietin is a major regulator of vascular
formation and organ growth, and erythropoietin receptors
are found in almost every embryonic tissue.4 Erythropoietin
receptors were found in many adult tissues including renal
tissue, and even the notion of autocrine or paracrine
erythropoietin systems has been raised.5,6 Although the
peritubular fibroblasts are the major adult site for erythro-
poietin production, erythropoietin receptors have been
demonstrated also in other kidney cell types, e.g., proximal
tubule epithelial cells, mesangial cells, and the glomerulus.6
Moreover, erythropoietin has important cytoprotective effects
on various cell lines and organs, and protection from ischemic
injury and inhibition of apoptotic death–related pathways has
been reported in the brain, heart, and renal tissue.7–10 The
intracellular pathways involved in these favorable erythro-
poietin effects may involve nuclear translocation of the
transcription factor nuclear factor-kB, JAK2 phosphorylation,
and phosphorylation of Akt (protein kinase B).10,11
An experimental study revealed that cobalt administration
to rats caused upregulation of erythropoietin, and dimin-
ished the degree of renal injury caused by ischemia–reper-
fusion, suggesting that erythropoietin may also have an
important role in renal ischemic preconditioning.12 Indeed,
subsequent studies from different laboratories demonstrated
that preconditioning with recombinant human erythropoietin
(rHuEPO) is protective against ischemia–reperfusion injury in
rodents.13–16 In this respect, data on specific protective effects
of rHuEPO and its analogs on endothelial cells of glomeruli
and tubulo-interstitial capillaries are of particular interest.10
Furthermore, administration of rHuEPO may not only have
protective effects on the vascular level but might also enhance
the potential for regeneration, as we have demonstrated that
erythropoietin stimulates proliferation and differentiation of
functionally active endothelial progenitor cells in preclinical
models.17 These bone marrow-derived cells orchestrate
endothelial and vascular repair mechanisms.
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Renal ischemia, whether caused by shock or after surgery,
is a major cause of acute kidney injury in men.18,19 In this
respect, kidney transplantation is a classical model of acute
kidney injury due to ischemia–reperfusion injury, as the
transplanted organ is connected to the recipients blood
supply usually after several hours of ‘cold ischemia’.
Reperfusion, although essential for the survival of ischemic
tissue, initiates a complex and interrelated sequence of events
that result in injury and the eventual death of renal cells
due to a combination of both apoptosis and necrosis.20–22
Apoptotic cell death has been documented in human biopsies
after renal ischemia–reperfusion, and inhibition of apoptotic
signaling and cell death ameliorates the associated injury and
inflammation in an experimental model of ischemic acute
kidney injury.22 Similarly, ischemia–reperfusion damage of
transplanted kidney is thought to be a major factor limiting
renal function after successful transplantation.23,24 As long-
term outcome is mainly predicted by graft function 12
months after successful transplantation, therapeutic regimens
preventing ischemia–reperfusion injury and maintaining
stable renal function are still needed.25
Administration of rHuEPO has been shown to reduce
apoptosis in experimental models of acute and chronic renal
ischemic injury. Thus, preconditioning and/or treatment
with rHuEPO may also prevent renal tissue damage and loss
of function as a result of ischemia–reperfusion injury after
successful kidney transplantation. Despite these promising
preclinical data, it is unclear weather rHuEPO treatment is
also beneficial in patients after kidney transplantation. We
therefore evaluated short-term and long-term effects of high-
dose rHuEPO treatment in deceased donor kidney transplant
recipients in a prospective double-blind, placebo-controlled
study.
RESULTS
From the 90 patients enrolled and randomized to one of the
two treatment arms, one patient in the rHuEPO arm did not
receive active treatment because of a medical condition
(dissection of the transplant artery before injection), and one
patient in the placebo arm because of protocol violation (the
study drug was not administered). All other patients received
their assigned treatment (44 in the rHuEPO group and 44 in
the placebo group). We analyzed data of these 88 patients on
an intention-to-treat basis.
Baseline clinical characteristics of patients randomized to
both treatment groups are presented in Table 1. They were
comparable with respect to gender, age, body mass index, or
pre-transplantation hemoglobin, as well as dialysis vintage.
Mean estimated glomerular filtration rate (eGFR) was
comparable in rHuEPO and placebo-treated patients 6 weeks,
6 months, and 12 months after transplantation (Figure 1 and
Table 2). There was also no significant difference between
groups with respect to the incidence of delayed graft function
(10/44 patients rHuEPO vs. 14/44 patients with placebo).
Table 2 summarizes additional outcome data. Patient and
graft survival showed no statistical difference over the study
Table 1 | Baseline clinical data of deceased donor kidney
allograft recipients randomized to receive either rHuEPO or
placebo treatment
rHuEPO
(n=44)
Placebo
(n=44) P-value
Gender (female/male) 19/25 18/26 0.8741
Age (years) 53.6±1.8 49.8±1.6 0.6770
Body mass index (kg/m2) 25.3±0.6 25.9±0.6 0.8273
Dialysis vintage (months) 88.4±5.1 67.6±4.9 0.0651
Pre-transplant hemoglobin (g/dl) 12.7±0.2 12.3±0.2 0.0535
Pre-transplant hsCRP (mg/l) 6.3±2.3 8.6±2.2 0.4399
Cold ischemia time (min) 751±38 807±46 0.1876
HLA mismatches 2.7±0.3 2.2±0.3 0.7871
Abbreviations: HLA, human lymphocyte antigen; hsCRP, serum high-sensitivity
C-reactive protein; rHuEPO, recombinant human erythropoietin.
Data are presented as mean±s.e.m.
120 NS
100
90
80
70
e
G
FR
 (m
l/m
in 
pe
r 1
.73
 m
2 )
60
50
40
30
20
10
0
6 Weeks
rHuEPO Placebo
NS
6 Months
rHuEPO Placebo
110
120
100
90
80
70
e
G
FR
 (m
l/m
in 
pe
r 1
.73
 m
2 )
60
50
40
30
20
10
0
110
NS
12 Months
rHuEPO Placebo
120
100
90
80
70
e
G
FR
 (m
l/m
in 
pe
r 1
.73
 m
2 )
60
50
40
30
20
10
0
110
Figure 1 | Estimated glomerular filtration rate (eGFR; based on
chronic kidney disease–Epidemiology Collaboration equation)
in deceased donor kidney allograft recipients randomized to
recombinant human erythropoietin (rHuEPO) or placebo 6
weeks, 6 months, and 12 months after transplantation. Non-
survivors were excluded from the analysis. NS, not significant.
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observation period between groups. The cause of death is
unknown for one patient in the rHuEPO treatment group
(239 days after transplantation with a functioning graft). The
causes of death in two patients of the placebo group were
liver failure with consecutive multi-organ failure and dialysis
dependency (146 days after transplantation) and sudden
death (338 days after transplantation). Graft loss in the
rHuEPO treatment group occurred because of renal venous
thrombosis in two patients, insufficiency of renal artery
anastomosis in one patient, and bend stenosis in another
patient. In the placebo treatment group, graft loss occurred as
a result of cholesterol embolism and renal infarction (n¼ 1),
renal artery thrombosis with consecutive renal infarction
(n¼ 1), severe pyelonephritis with interstitial fibrosis (n¼ 1),
and granulomatous interstitial nephritis with severe vascular
rejection (n¼ 1). The amount and severity of ‘non-kidney’
adverse events were similar between the two groups as well:
small intestine perforation occurred in one patient assigned
to the rHuEPO treatment group, whereas in the placebo
treatment group subclavian vein thrombosis (n¼ 1), ureteral
necrosis (n¼ 1), and bilateral pulmonary embolism (n¼ 1)
occurred.
In rHuEPO-treated patients, we observed a slightly but
significantly higher mean hemoglobin level 2 and 4 weeks
after transplantation (Figure 2), but 6 weeks after transplan-
tation mean hemoglobin levels in both treatment groups
were not significantly different. No patient needed conven-
tional rHuEPO therapy within the first 6 months after
successful kidney transplantation, and the number of blood
transfusions in this period was comparable in both treatment
arms (Table 2).
A total of 72 null biopsy specimens were available for
examination (34 in the rHuEPO and 38 in the placebo
group), whereas we obtained renal tissue specimens in 60
patients 6 weeks after transplantation (32 in the rHuEPO and
28 in the placebo group), and in 55 patients at 6 months after
transplantation (31 in the rHuEPO and 24 in the placebo
group). The missing biopsies were not performed either
because of technical reasons or withdrawal of patients’
consent for the biopsy. Histological assessment showed no
significant differences in several parameters of acute and
chronic allograft tissue changes at the respective time
points, i.e., in null biopsies (Table 3), 6 weeks (Table 4)
and 6 months after transplantation (Table 5). Similarly, the
total number of biopsy-proven acute rejections in all protocol
biopsies 6 weeks and 6 months after transplantation was not
Table 2 | Outcome data of deceased donor kidney allograft recipients randomized to treatment with rHuEPO or placebo
(intention-to-treat analysis)
rHuEPO Placebo P-value Difference of means (95% CI)
eGFR at 6 weeks (ml/min) 46.6±4.3 (n=44) 46.8±3.0 (n=44) 0.5097 0.2 (10.3 to 10.0)
eGFR at 6 months (ml/min) 40.4±3.2 (n=44) 42.7±3.4 (n=43) 0.4198 2.3 (11.5 to 7.0)
eGFR at 12 months (ml/min) 40.6±3.3 (n=43) 43.6±3.8 (n=42) 0.5561 3.0 (12.9 to 7.0)
Delayed graft function 10/44 (23%) 14/44 (32%) 0.6791
Patient survival
6 Weeks 44/44 (100%) 44/44 (100%) 0.9587
6 Months 44/44 (100%) 43/44 (98%) 0.9139
12 Months 43/44 (98%) 42/44 (95%) 0.9343
Functioning grafts
6 Weeks 40/44 (91%) 44/44 (100%) 0.7845
6 Months 40/44 (91%) 40/44 (91%) 0.9731
12 Months 39/43 (89%) 36/42 (82%) 0.8862
Transfusions
Patients 12 (27%) 15 (34%) 0.2612
Blood packs 53 61 0.2188
Hospitalization (days) 19.2±11.5 22.4±16.2 0.2962
Abbreviations: CI, confidence interval; eGFR, estimated glomerular filtration rate; rHuEPO, recombinant human erythropoietin.
We found no significant differences between the two treatment groups. Data are presented as mean±s.e.m.
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Figure 2 |Mean hemoglobin levels in deceased donor kidney
allograft recipients randomized to recombinant human
erythropoietin (rHuEPO) or placebo during the first 6 weeks
after transplantation. NS, not significant.
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significantly different between the two treatment arms; i.e., 7
in the rHuEPO group and 11 in the placebo group.
DISCUSSION
In the present prospective, double-blind, placebo-controlled
trial, we evaluated short-term (6 weeks) and long-term (12
months) effects of high-dose rHuEPO in deceased donor
kidney transplant recipients. The rationale for this study
arose from findings of several experimental studies in which
administration of rHuEPO was protective against ischemia–
reperfusion injury in rodents.13–16 In contrast to these
promising experimental data, we did not observe a significant
effect of rHuEPO on kidney transplant function, nor on the
frequency of delayed graft function. Importantly, this clinical
outcome was corroborated by the results of graft tissue
histology obtained at predefined time points during our
routine control biopsy program.26,27 Here, we also found no
significant differences between treatment groups with respect
to acute and chronic renal tissue changes at an early (6
weeks) and late (6 months) time point. Furthermore, we have
to emphasize that null biopsies were available, making the
scoring and comparison of tissue injury between the two
treatments even more robust. To our knowledge, this is the
first controlled study in humans using high-dose erythro-
poietin treatment on different tissue injury parameters, e.g.,
acute tubular injury (ATI). As we observed rather large
confidence intervals of the differences between groups, we
cannot definitely exclude the possibility that in a much larger
number of patients administration of rHuEPO might have
had a positive effect on kidney graft function. However, from
a practical, as well as economical, perspective, it is
questionable whether a modest effect of rHuEPO therapy
would justify such a labor-intensive and costly treatment in
the clinical setting of kidney transplantation.
Our clinical outcome data are in agreement with those of
Martinez et al.,28 who studied high-dose rHuEPO in the
setting of deceased donor kidney transplantation, and of
Endre et al.,29 who studied high-dose rHuEPO in the setting
of acute kidney injury. In the French open-label multicenter
randomized study,28 the effect of high-dose epoetin-b
administered during the first 2 weeks of renal transplantation
was assessed in 104 patients at risk for delayed graft function.
Epoetin-b (30,000 IU each) was administered before surgery
and at 12 h, 7 days, and 14 days post transplantation. The
control group received no treatment. At 1 month post
transplant, the eGFR (Modification of Diet in Renal Disease
(MDRD) Study formula) was 42.5±19.0 ml/min in the
epoetin-b group and 44.0±16.3 ml/min in the control group;
the difference was not significant. These data are almost
identical to our finding on the eGFR 6 weeks after
transplantation. In addition, the French authors did not find
a significant difference in the frequency of delayed graft
function (32.0% vs. 38.8%), which is also congruent with our
results. Moreover, they found no difference in the incidence
of serious adverse events, and, particularly, the number of
venous or arterial thromboses was not increased.
In contrast to the French study, we now provide for the
first time long-term data and histological assessment of the
graft after high-dose rHuEPO treatment. Moreover, in
contrast to the open-label design of the French study, we
used the gold standard of clinical study designs, a double-
blind, placebo-controlled study. In addition, we administered
our first rHuEPO dose directly into the transplant artery
Table 3 | Histological data from null biopsies of deceased
donor kidney allografts in patients randomized to rHuEPO or
placebo
rHuEPO (n=34) Placebo (n=38)
Acute tubular injury
No 2 1
Focal 2 4
Diffuse 30 33
Interstitial fibrosis
p10% 8 3
11–25% 0 0
425% 0 0
Abbreviation: rHuEPO, recombinant human erythropoietin.
Data presented are from available biopsies. We found no significant differences
between the two treatment groups.
Table 4 | Histological data from regular 6-week control
biopsies of deceased donor kidney allografts in patients
randomized to rHuEPO or placebo
rHuEPO (n=32) Placebo (n=28)
Acute tubular injury
No 12 4
Focal 6 9
Diffuse 14 15
Interstitial fibrosis
p10% 31 24
11–25% 1 3
425% 0 1
BPAR 0 2
Abbreviations: BPAR, biopsy-proven acute rejection (including borderline rejection);
rHuEPO, recombinant human erythropoietin.
Data presented are from available biopsies. We found no significant differences
between the two treatment groups.
Table 5 | Histological data from regular 6-month control
biopsies of deceased donor kidney allografts in patients
randomized to rHuEPO or placebo
rHuEPO (n=31) Placebo (n=24)
Acute tubular injury
No 8 7
Focal 9 5
Diffuse 14 12
Interstitial fibrosis
p10% 24 16
11–25% 3 4
425% 4 4
BPAR 7 9
Abbreviations: BPAR, biopsy-proven acute rejection (including borderline rejection);
rHuEPO, recombinant human erythropoietin.
Data presented are from available biopsies. We found no significant differences
between the two treatment groups.
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immediately before opening of the clamp in order to
maximize a possible effect on reperfusion injury, whereas in
the French trial all administrations were intravenous. Even
with such a demanding approach we could not find an effect
of rHuEPO on kidney graft function. In the other double-
blind, placebo-controlled trial, the authors studied early
treatment with rHuEPO on the development of acute kidney
injury in 162 patients in two general intensive care units.29
Patients received an intravenous dose of 500 U per kg body
weight to a maximum dose of 50,000 IU. The primary
outcome was the average plasma creatinine increase from
baseline over a period of 4–7 days. The authors found no
difference in the incidence of rHuEPO-specific adverse
events, nor in the primary outcome between the placebo
and treatment groups.
It is possible that the rHuEPO dose that we used in our
study was too low to protect against ischemia–reperfusion
injury after kidney transplantation. However, we administered
a single rHuEPO dose of 40,000 IU, which corresponds to
about 500 IU per kg body weight in an 80-kg patient, whereas
the total rHuEPO dose administered in our study was
120,000 IU, which corresponds to about 1500 IU per kg body
weight in an 80-kg patient. The doses used in different
experimental models of acute kidney injury, including ische-
mia–reperfusion injury, ranged from 300 to 5000 IU per kg
body weight and were thus comparable with the dose we used
in the present study. Moreover, in their study, Sharples et al.14
significantly reduced glomerular dysfunction and tubular
injury in rats by administration of only 300 U rHuEPO per
kg body weight. In contrast to the beneficial effect of rHuEPO
administration on renal tissue histology in these animal
experiments,14,30 we observed no effect of rHuEPO even at a
late time point 6 months after transplantation. It is doubtful
whether a favorable effect of an acute rHuEPO treatment
within the first 7 days post transplantation will unmask even
later; i.e., years after transplantation. Another important
inherent limitation of our study design in the clinical setting
of organ transplantation is the timing of the intervention with
rHuEPO in relation to the initiation of ischemia–reperfusion.
With the intervention taking place after the harvesting of
kidneys for transplantation, we are probably able to prevent
reperfusion injury, but not ischemia, to the harvested organ to
some extent. This point is important, as results of animal
studies have indicated that high-dose rHuEPO treatment may
be more efficient for prevention of ischemia than for
prevention of reperfusion injury.14,30
Importantly, in all trials published so far, no significant
safety problems even with high rHuEPO doses in clinical
settings of acute kidney injury could be observed. This point is
pertinent, as the use of such high doses has raised concerns
regarding thrombosis, high blood pressure, and seizures. In the
present study, we found no increase in adverse events as
compared with the placebo treatment group despite a
temporarily significantly higher mean hemoglobin level in
the rHuEPO-treated patients—particularly, there was no
evidence for increased intravascular thrombosis. Our primary
end point was the difference in eGFR between treatment
groups calculated after the chronic kidney disease-
Epidemiology Collaboration equation, which is validated in
the setting of kidney transplantation. However, even after
calculation of eGFR using other equations such as the MDRD-
based eGFR, or the measurement of cystatin C (data not
shown), we did not observe a significant difference between
the treatment groups at all time points studied. In addition,
these robust clinical results are also supported by the
histological findings. One limitation of the study is that the
power analysis was based on the assumption that the standard
deviation of the GFR would be below 20 ml/min. Hence, with
the actually observed standard deviation slightly above this
value, the study might not be adequately powered to exclude
the possibility of a modest rHuEPO effect on graft func-
tion. Finally, we could speculate that a lack of erythropoietin
receptor expression by tubular cells after ischemic tubular cell
death could prevent efficacy of rHuEPO in this clinical setting.
Thus, as already discussed above, preconditioning with high-
dose rHuEPO before ischemic injury and cell death could be
more effective in preventing tubular necrosis than adminis-
tration immediately before reperfusion takes place.
Although we used high-dose rHuEPO treatment in the
present study, the results obtained are nevertheless in line
with those from large randomized controlled trials for
correction of anemia in patients with chronic kidney disease,
where no effect of long-term treatment with standard
rHuEPO doses on the progression of kidney disease was
documented.31–33 Moreover, in the Trial to Reduce Cardio-
vascular Events with Aranesp Therapy study, the incidence
of stroke was even significantly higher in the darbepoetin-a
treatment cohort.33 Finally, in recently published trials in
patients with stroke and in patients with ST-segment
elevation myocardial infarction, increased adverse effects
rather than a benefit of high-dose rHuEPO therapy was
observed.34,35 The dialysis vintage tended to be different
between the two groups despite the randomization proce-
dure, which might have influenced the outcome.
Taken together, our results show that administration of
rHuEPO was safe and well tolerated in deceased donor
kidney allograft recipients, but without a significant effect on
short-term and long-term outcome.
MATERIALS AND METHODS
Patients
Ninety dialysis patients undergoing deceased donor kidney trans-
plantation were enrolled. Patients with preformed antibodies, i.e.,
highly immunized patients, were excluded from the study.
Detailed information on enrollment of patients into the study is
provided in the CONSORT flow diagram in Figure 3. All patients
received a standard immunosuppressive regimen comprising inter-
leukin-2 antibodies (20 mg basiliximab on day 0 and day 4),
calcineurin inhibitors (cyclosporine A or tacrolimus), mycopheno-
late mofetil (1000 mg twice daily), and steroids (local tapering
protocol, minimum dose 5 mg per day). The study population
comprised patients aged 18–70 years with deceased donor kidney
transplants.
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Major specific exclusion criteria due to the rHuEPO treatment
were significant cardiovascular events within 6 months before
transplantation (e.g., myocardial infarction, stroke, transient
ischemic attack, PRIND, thrombosis of large vessels), higher-grade
occlusive disease of cerebral and/or peripheral arteries, any kind of
hematological, bleeding, or thromboembolic disorders, acute or
chronic inflammatory disorders (e.g., vasculitis, systemic lupus
erythematodus), decompensated metabolic or liver diseases, un-
controlled hypertension, and a hemoglobin concentration of less
than 8.0 g/dl and above 14.0 g/dl. Other key exclusion criteria
included the following: recipients of a second transplant who
experienced immunological graft loss of their first graft within 1
year, living donor grafts, cold ischemia time longer than 24 h,
recipients of multiple organ transplants, recipients of ABO-
incompatible transplants, patients with a historical peak panel-
reactive antibody 425%, patients with existing antibodies against
human leukocyte antigens of the donor organ, and history of
malignancy in the past 5 years.
Study design
The study was approved by the Ethics Committee of the Hannover
Medical School. Appropriate reporting of the Ethics Committee
approval to national and European regulatory bodies was made
(EudraCT-number 2006-002938-38). We used a prospective double-
blind, placebo-controlled, parallel group single-center study design.
Recruitment started in February 2007 and was completed in May
2009. After written informed consent, all patients were randomly
assigned to receive either 40,000 IU rHuEPO, i.e., epoetin-a, or
placebo treatment. Both placebo- and verum (¼ rHuEPO)-contain-
ing vials were produced and provided by Janssen-Cilag GmbH
(Neuss, Germany). Vials containing rHuEPO and those containing
placebo had identical appearance and were thus indistinguishable
for the investigators. They were identified only by the randomiza-
tion number. The first intra-arterial injection of rHuEPO or placebo
was administered already in the operation theater immediately
before reperfusion directly into the iliac artery proximal to the
anastomosis of the graft artery with clamped distal iliac artery in
order to supply the full dose of rHuEPO into the reperfused kidney
graft (after the vascular clamp was removed from the transplant
renal artery). The second and third dose of 40,000 IU rHuEPO or
placebo were administered intravenously on days 3 and 7 after
successful transplantation. The rationale for the rHuEPO dose used
and the number and timing of injections applied was primarily
based on available experimental data,13–16 and data from a recently
published study with high-dose rHuEPO treatment in patients
with stroke,31 where a similar design and cumulative rHuEPO dose
was used.
Red blood cell transfusions could have been given to patients in
both study arms in order to maintain the hemoglobin level above
9.0 mg/l during the study period, whereas the hemoglobin
concentration should not exceed 13.0 g/dl.
All relevant information with respect to the surgical intervention
was recorded; i.e., duration of the intervention, duration of cold
ischemia, blood pressure drops, and so on. We also assessed the
frequency and duration of renal replacement therapy in each patient
after transplantation and the individual need for blood transfusions.
Furthermore, blood pressure was monitored and the co-medication
recorded after transplantation on a regular basis. We assessed the
following clinical and laboratory parameters before transplantation
and at regular intervals thereafter: serum creatinine, eGFR based on
the chronic kidney disease-Epidemiology Collaboration equation
formula, endogenous creatinine clearance (when available), blood
count, and inflammatory markers. Delayed graft function was
defined as urine output of less than 500 ml in the first 24 h after
transplantation and/or need of dialysis because of graft dysfunction
within the first week after transplantation.
Last but not least, we also evaluated available data from renal
histology examination in kidney specimens obtained during routine
protocol biopsies (Hannover Medical School Transplant Biopsy
Program) of kidney grafts before transplantation (null biopsies), as
well as 6 weeks and 6 months after successful transplantation.26,27
Examination of tissue specimens was performed in a blinded
manner by one experienced pathologist. ATI was diagnosed if one or
more of the following histological features were present: epithelial
Screening:
February 2007 – April 2009
420 Patients
Enrollment
90 Patients
1 Patient without
medication
(dissection of the renal
artery before injection)
45 Patients
rHuEPO
44 Patients
rHuEPO
45 Patients
Placebo
330 Patients
• Age less than 18 years 28
94• Living donor transplantation
5• Highly immunized
41• Multi-organ transplantation
57• Other study
63• Refused to participate
42• Medical reasons
  (exclusion criteria like anemia)
44 Patients
Placebo
1 Patient without
medication
(unknown reason)
Figure 3 |CONSORT flow diagram on enrollment of patients into the study. Ninety patients undergoing deceased donor kidney
transplantation were enrolled, and 88 were finally randomized to one of the two treatment arms; i.e., high-dose recombinant human
erythropoietin (rHuEPO) or placebo.
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swelling with lucency of the cytoplasm, loss of brush border, luminal
dilatation with flattening of the epithelium, and cytoplasmatic
vacuolization. ATI was semiquantitatively graded as mild when only
a single tubule or a focal group of nephrons was involved, or as
severe when at least two foci with several nephrons showed
histological signs of ATI. No further sub-analysis of the localization
of ATI (outer/inner cortex, specific nephron segments) was carried
out. From all biopsies with sufficient material (comprising renal
cortical tissue with at least one artery), the interstitial infiltrates were
evaluated in a quantitative manner.
Statistical analysis
The primary study end point was allograft function 6 weeks after
transplantation; i.e., chronic kidney disease-Epidemiology Collabo-
ration equation-based eGFR. Secondary end points were incidence
of delayed graft function and eGFR at 6 and 12 months after
transplantation. Data from both treatment arms were compared
using a t-test for random data. With a difference of at least
12 ml/min in eGFR between groups, the number of patients enrolled
per group (n¼ 45) would allow the detection of a significant
difference in eGFR between groups at a 5% level (Po0.05) with a
power of 80%. We also analyzed histology parameters in renal tissue
specimens obtained before transplantation (null biopsies) and
during regular control biopsies of kidney grafts 6 weeks and 6
months after transplantation. All data are shown as mean±s.e.m.,
and 95% confidence interval where indicated. Confidence interval
was calculated using Prism Graph version 5.0. (La Jolla, CA). As
graft lost due to death that is unrelated to the treatment and should
not confound the analysis of the treatment effect on eGFR, we have
included only survivors in the analysis of the primary end point
(graft function).
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